Status:
COMPLETED
JAK Inhibitors' Efficacy in Bullous Pemphigoid
Lead Sponsor:
Chao Ji
Conditions:
Bullous Pemphigoid
Janus Kinase Inhibitor
Eligibility:
All Genders
Brief Summary
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering skin disease that predominantly affects the elderly population, with rare cases reported in children and adolescents. BP is characteriz...
Detailed Description
This study will conduct a retrospective review of patients with Bullous pemphigoid in the Department of Dermatology of the First Affiliated Hospital of Fujian Medical University. Researchers will init...
Eligibility Criteria
Inclusion
- Diagnosis of Bullous pemphigoid;
- Moderate to severe bullous pemphigoid； The disease severity was measured using the Bullous Pemphigoid Disease Area Index (BPDAI) score and was classified into mild (BPDAI ≤ 19), moderate (20 ≤ BPDAI ≤ 56), and severe (BPDAI ≥ 57).
- Moderate to severe BP received JAK Inhibitors combination with corticosteroids therapy；
Exclusion
- Patients diagnosed with malignant neoplasms
- Previous administration with biologics within 3 months
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06561256
Start Date
January 1 2022
End Date
July 31 2024
Last Update
September 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Fujian Medical University
Fujian, Fuzhou, China, 350000